CTLA-4 inhibitors that have been approved by the FDA include Ipilimumab and Tremelimumab, etc. A phase II clinical trial showed that 20 patients with diagnosed advanced HCC were treated with Tremelimumab, ORR was 17%, disease remission rate (DCR) was 76.4%, and median progress free survival (PFS) was 6.48 months (48). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.